Biotronik’s ECOST study shows that the device maker’s ICD home monitoring reduces inappropriate shocks by half and helps extend device battery life. Cardiovascular medical device maker Biotronik unveiled clinical results from its Effectiveness & Cost of ICD Follow-Up Schedule with Telecardiology trial, which showed that the company’s home monitoring system reduced inappropriate implantable cardioverter defibrillator shocks by 52% while extending the device’s battery-life. “Developing safe, innovative, effective therapies to improve patient health is Biotronik’s number 1 priority,” Biotronik international president Christoph Böhmer said in prepared remarks. “Biotronik Home Monitoring enhances the patient’s quality of life and simplifies patient treatment.” The study was based on 433 patients from 43 sites throughout France, who were followed over a period of 27 months. The 221 home-monitored patients were brought in to an ambulatory department once per year and the 212 control patients underwent in-office visits every 6 months, according to a press release.
